Print Page   |   Sign In   |   Join ISSX
ISSX News: General

Ann K. Daly Selected as ISSX Award Winner

Tuesday, May 30, 2017   (0 Comments)
Share |

The 2017 European Distinguished Scientific Achievement Award is presented to an ISSX member who has made major scientific contributions to the field. The purpose of this award is to recognize meritorious contributions by senior or mid-career scientists who have had a major impact on research in the area of drug metabolism and pharmacokinetics.  It signifies achievement and delineates the best of the best within the region.  ISSX is extremely proud to bestow this year’s award upon Ann K. Daly, Professor of Pharmacogenetics at the Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.


Professor Daly received her PhD from the University of Dublin (Trinity College), performing biochemical studies on aldo-keto reductases and glutathione S-transferases under the direction of Dr. Tim Mantle. She subsequently worked on nuclear structure at the University of Geneva with Professor Ulrich Laemmli and then moved to Newcastle University, working initially on the molecular biology of retinoic acid action. In 1989, she joined the newly formed Pharmacogenetics group at Newcastle. Her current research is focused on the pharmacogenetics of the human cytochrome P450, genetic susceptibility to adverse drug reactions and the genetics of complex diseases, particularly liver disease.

Professor Daly has had a major impact in the direction of the research in the area encompassing the interests of ISSX including:

  • Identification of novel alleles and characterization of genotype-phenotype relationships for CYP2D6. She contributed to the discovery of the main CYP2D6 variant alleles associated with the poor metabolizer phenotype and performed detailed studies on phenotype-genotype relationships. She also led the development of a nomenclature scheme for CYP2D6 alleles which continues to serve as a basis for this P450 gene and genes encoding other P450 isoforms.

  • Pharmacogenetics of Warfarin:  Professor Daly showed that those with CYP2C9 alleles associated with decreased activity had a lower warfarin dose requirement and an increased risk of bleeding when treated with this drug. She subsequently demonstrated that the VKORC1 gene also affected dose requirements and devised dosing algorithms incorporating both genotypes. More recently, she was a member of a consortium that tested a genotype-based dosing algorithm in a clinical trial and found that incorporating genotype in dosing was associated with a significantly improved clinical response.

  • Drug-induced Liver Injury - Pharmacogenomic Studies:  She has identified a number of novel genetic predictors of drug-induced liver injury, a rare but serious complication of treatment with a range of widely prescribed drugs. In particular, she has demonstrated the importance of certain HLA alleles, especially HLA-B*57:01, in predicting susceptibility but also demonstrated a drug-specific role for genes relevant to drug disposition (e.g. UGT and ABCC2). She leads the iDILIC consortium which aims to identify novel genetic factors contributing to drug-induced liver injury and involves European and other international investigators.

  • Genomics of  Liver Disease: Professor Daly has shown that genotype for a common variant in PNPLA3 is an important risk factor for progression of both alcoholic liver disease and non-alcoholic liver disease to fibrosis and hepatocellular carcinoma. A variant in TM6SF2, another gene coding for a protein relevant to lipid processing, was also demonstrated to be a risk factor for progression to fibrosis.

  • Studies on Retinoid Biology: She demonstrated the existence of the nuclear receptor RARalpha which binds alltrans retinoic acid (prior to its subsequent cloning by others). Later, she performed studies on the role of cytochrome P450 isoforms in all-trans retinoic acid metabolism showing a key role for CYP2C8. Following detection and characterisation of novel CYP2C8 alleles, she demonstrated that CYP2C8 variant alleles do not account for interindividual variation in 13-cis retinoic acid pharmacokinetics.


Ann Daly is Chair of IUPHAR (The International Union of Basic and Clinical Pharmacology) Drug Metabolism and Transporter Section Executive Board; a member of the IUPHAR Pharmacogenetics Subcommittee; Committee Member of the UK Pharmacogenetics and Stratified Medicine Network; Editor of The Human Cytochrome P450 (CYP) Allele Nomenclature Database; Executive Editor of the British Journal of Clinical Pharmacology; and an Editorial Board Member of Clinical Pharmacology & Therapeutics, Pharmacogenetics & Genomics, Journal of Pharmacology & Experimental Therapeutics, Pharmacogenomics, Pharmacogenomics Journal.  She also has given much of her past time in service to ISSX as a member of Council.

To recognize and celebrate Professor Daly’s substantial and sustained scientific contributions to the field of xenobiotic disposition spanning more than four decades, she is awarded the 2017 ISSX European Scientific Achievement Award.

Professor Daly will receive the award and deliver the award lecture at the 14th European Meeting of ISSX on June 29, 2017.

Association Management Software Powered by YourMembership  ::  Legal